Payment overview · 2025
General Payments
$366.38
17 reported records · 11 companies
Healthcare provider profile · identity verified
George Fredrick Herdel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW SMYRNA BEACH, FL · NPI 1457313421
Verified facts
What the public records show
CMS Open Payments records show George Fredrick Herdel, M.D. received $366.38 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.44 | 29.6% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $42.89 | 11.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.35 | 10.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.51 | 9.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.98 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.42 | 6.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.89 | 6.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.27 | 5.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.87 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.35 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.41 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.00 | 16 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.88 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.31 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 333 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
141 | 36 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
333 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1356 | 362 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1245 | 344 |
| Amlodipine Besylate | Amlodipine Besylate | 999 | 293 |
| Lisinopril | Lisinopril | 897 | 253 |
| Losartan Potassium | Losartan Potassium | 836 | 227 |
| Tramadol Hcl | Tramadol Hcl | 702 | 166 |
| Alprazolam | Alprazolam | 660 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 635 | 191 |
| Pravastatin Sodium | Pravastatin Sodium | 630 | 173 |
| Metformin Hcl | Metformin Hcl | 570 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 150 |
| Simvastatin | Simvastatin | 526 | 145 |
| Lorazepam | Lorazepam | 499 | 119 |
| Omeprazole | Omeprazole | 492 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 420 | 127 |
| Hydrochlorothiazide | Hydrochlorothiazide | 400 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 392 | 113 |
| Temazepam | Temazepam | 382 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 367 | 87 |
| Gabapentin | Gabapentin | 343 | 105 |
| Eliquis | Apixaban | 333 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 97 |
| Meloxicam | Meloxicam | 303 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 80 |
| Allopurinol | Allopurinol | 281 | 74 |
| Montelukast Sodium | Montelukast Sodium | 275 | 83 |
| Potassium Chloride | Potassium Chloride | 269 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 264 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 73 |
| Furosemide | Furosemide | 232 | 65 |
| Atenolol | Atenolol | 229 | 62 |
| Bupropion Xl | Bupropion Hcl | 219 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 74 |
| Trazodone Hcl | Trazodone Hcl | 216 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 206 | 70 |
| Alendronate Sodium | Alendronate Sodium | 204 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 74 |
| Sertraline Hcl | Sertraline Hcl | 194 | 62 |
| Valsartan | Valsartan | 188 | 60 |
| Ozempic | Semaglutide | 171 | 30 |
| Glipizide Er | Glipizide | 164 | 46 |
| Carvedilol | Carvedilol | 161 | 47 |
| Synthroid | Levothyroxine Sodium | 141 | 36 |
| Donepezil Hcl | Donepezil Hcl | 140 | 42 |
| Famotidine | Famotidine | 132 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 35 |
| Pregabalin | Pregabalin | 128 | 43 |
| Diazepam | Diazepam | 126 | 32 |
| Metformin Hcl Er | Metformin Hcl | 119 | 37 |
| Ezetimibe | Ezetimibe | 117 | 36 |
| Methylprednisolone | Methylprednisolone | 116 | 105 |
| Clonazepam | Clonazepam | 105 | 26 |
| Benazepril Hcl | Benazepril Hcl | 101 | 29 |
| Lovastatin | Lovastatin | 99 | 23 |
| Buspirone Hcl | Buspirone Hcl | 94 | 25 |
| Irbesartan | Irbesartan | 91 | 25 |
| Mirtazapine | Mirtazapine | 87 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 84 | 66 |
| Warfarin Sodium | Warfarin Sodium | 84 | 22 |
| Glipizide | Glipizide | 80 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 27 |
| Primidone | Primidone | 76 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 34 |
| Valacyclovir | Valacyclovir Hcl | 73 | 35 |
| Celecoxib | Celecoxib | 72 | 22 |
| Glimepiride | Glimepiride | 72 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 20 |
| Xarelto | Rivaroxaban | 70 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 20 |
| Memantine Hcl | Memantine Hcl | 67 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 16 |
| Ketoconazole | Ketoconazole | 66 | 29 |
| Sildenafil Citrate | Sildenafil Citrate | 65 | 22 |
| Finasteride | Finasteride | 63 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 16 |
| Enalapril Maleate | Enalapril Maleate | 59 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 59 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 15 |
| Azithromycin | Azithromycin | 54 | 49 |
| Fenofibrate | Fenofibrate | 53 | 15 |
| Acyclovir | Acyclovir | 52 | 22 |
| Repatha Sureclick | Evolocumab | 52 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 13 |
| Spironolactone | Spironolactone | 51 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 14 |
| Bumetanide | Bumetanide | 49 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 15 |
| Farxiga | Dapagliflozin Propanediol | 47 | 12 |
| Promethazine Hcl | Promethazine Hcl | 47 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 14 |
| Gemfibrozil | Gemfibrozil | 45 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Propranolol Hcl | Propranolol Hcl | 42 | 13 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | 11 |
| Cefdinir | Cefdinir | 40 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 25 |
| Estradiol | Estradiol | 38 | 17 |
| Amoxicillin | Amoxicillin | 37 | 27 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 37 | suppressed |
| Eszopiclone | Eszopiclone | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | 23 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Minoxidil | Minoxidil | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Prolia | Denosumab | 31 | 19 |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Ramipril | Ramipril | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 11 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $366.38 · 17 records | Novo Nordisk Inc | Arikayce, BREZTRI, Brinsupri, Cologuard Collection Kit, ELIQUIS, EVENITY, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error